tetrahydrocurcumin has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies
| Studies (tetrahydrocurcumin) | Trials (tetrahydrocurcumin) | Recent Studies (post-2010) (tetrahydrocurcumin) | Studies (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Trials (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) |
|---|---|---|---|---|---|
| 170 | 4 | 112 | 3,859 | 8 | 1,052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rajeswari, A; Sabesan, M | 1 |
1 other study(ies) available for tetrahydrocurcumin and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Curcumin; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Flavonoids; Male; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neurons; Parkinson Disease; Phenols; Polyphenols | 2008 |